Cannabis UseNCT07513337
Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)
A study testing Strain label and Claim in people with Cannabis Use, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.
Trial summary
This study looks at how cannabis product label and marketing claims affect product perceptions, use expectancies, and use intentions among inexperienced and experienced cannabis users. Participants will answer online survey questions on their perceptions of a cannabis product advertisement. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cannabis Use
- What is being tested?
- Strain label and Claim
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,035 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Apr 2026to 16 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age = 21+
- Live in in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
- For inexperienced users: lifetime cannabis use >1 \& <= 10
- For experienced users: lifetime cannabis use>10 \& <100, past month cannabis use>0
Who cannot join
- Under age 21
- Does not live in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
- Lifetime cannabis use >=100 times
- Lifetime cannabis use <1 time
- Lifetime cannabis use>10 \& <100 AND past month cannabis use=0
Trial locations and contacts
1 site in 1 country.
About this study
This study looks at how cannabis product label and marketing claims affect product perceptions, use expectancies, and use intentions among inexperienced and experienced cannabis users. Participants will answer online survey questions on their perceptions of a cannabis product advertisement.
Read the detailed description
This study aims to specify how product label and marketing claims affect product perceptions, use expectancies, and use intentions among cannabis users. A randomized 4 (Sativa, Indica, Hybrid, no strain label) x 3 (energizing, sedative, no claim) online experiment will be conducted with a sample of adults from states that have legalized adult cannabis recreational use. Our main research questions are: (1) Do label and marketing claim affect (a) harm perceptions, (b) subjective effects expectancies (e.g., arousal, sedation), (c) willingness to use, and (d) willingness to use during daily activities (e.g., driving)? and (2) Do label and marketing claim interact to affect product perceptions, use expectancies, and use intentions?
- Conditions
- Cannabis Use
- Being tested
- Strain label, Claim
- Keywords
- labeling and marketing, cannabis use, product perception
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Strain labelOther
Presentation of strain label on cannabis advertising material
ClaimOther
Presentation of claim on cannabis advertising material
| Study group | Role | What they receive |
|---|---|---|
| Indica/Energizing | Experimental | Ad features Indica label + energizing claim Receives: Other: Strain label; Other: Claim |
| Indica/Sedating | Experimental | Ad features Indica label + sedating claim Receives: Other: Strain label; Other: Claim |
| Indica/No claim | Experimental | Ad features Indica label + no claim Receives: Other: Strain label |
| Sativa/Energizing | Experimental | Ad features Sativa label + energizing claim Receives: Other: Strain label; Other: Claim |
| Sativa/Sedating | Experimental | Ad features Sativa label + sedating claim Receives: Other: Strain label; Other: Claim |
| Sativa/No claim | Experimental | Ad features Sativa label + no claim Receives: Other: Strain label |
| Hybrid/Energizing | Experimental | Ad features Hybrid label + energizing claim Receives: Other: Strain label; Other: Claim |
| Hybrid/Sedating | Experimental | Ad features Hybrid label + sedating claim Receives: Other: Strain label; Other: Claim |
| Hybrid/No claim | Experimental | Ad features Hybrid label + no claim Receives: Other: Strain label |
| No strain/Energizing | Experimental | Ad features no strain label + energizing claim Receives: Other: Claim |
| No strain/Sedating | Experimental | Ad features no strain label + sedating claim Receives: Other: Claim |
| No strain/No claim | No intervention | Ad features no strain label + no claim |
What is being measured
The primary outcome is the main question the study is designed to answer.
Harm perception - One time use
How harmful participant perceives the product to be after one time use. Participants will answer a survey item, In your opinion, what is the level of risk to one's health from using the product you just viewed one time?; with response options ranging from 0-Very low risk to 4-Very high risk.
Measured: Immediately after viewing ad
Harm perception - Daily use
How harmful participant perceives the product to be with daily use. Participants will answer a survey item, In your opinion, what is the level of health risk from using the product you just viewed on a daily basis?; with response options ranging from 0-Very low risk to 4-Very high risk.
Measured: Immediately after viewing ad
Expectancy effects
Effects participant expects to feel after using the product. Participants will answer a survey item, Please rate the extent to which you expect to feel each of the following effects [paranoid; panicked; fearful; anxious; suspicious; like my heart is racing; sluggish; drowsy; out of it; slow; lazy; excited; heightened senses; sociable; creative; wise; in tune with nature; focused; productive; sleepy; happy; euphoric; calm; relaxed; pain-free] after using the product you just viewed; with response options ranging from 0-not at all to 10-extremely.
Measured: Immediately after viewing ad
Willingness to use
How willing participant is to use the product. Participants will answer a survey item, How willing would you be to use the product you just viewed?; with response options ranging from 0-Not at all willing to 4-Very willing.
Measured: Immediately after viewing ad
Willingness to use during daily activities
How willing participant is to use the product during daily activities. Participants will answer a survey item, How willing would you be to use the product you just viewed if you [wanted to concentrate; wanted to relax; wanted to socialize; wanted to do a creative activity (e.g., art, music); wanted to feel happier; wanted to relieve medical symptoms/treat a medical condition/mental health condition; were going to drive a car in the next 30 minutes; were going to bed in the next 30 minutes; were planning to stay home for the next several hours; were going to work in the next 30 minutes; were at a party]?; with response options ranging from 0-Not at all willing to 4-Very willing.
Measured: Immediately after viewing ad
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start15 Apr 2026
- Primary completion16 Jul 2026
- Study completion16 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabis UseStudies of the same condition, open and under way.
- More trials run by Johns Hopkins Bloomberg School of Public HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 3,035 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- Meghan Moran, PhD, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513337
- Sponsor's protocol ID
- IRB00034819
- Other IDs
- 5R01DA059584
- Status last verified
- Sep 2026
- First submitted
- 1 Apr 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified participant responses will be shared as needed to comply with grant and publication policies.
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)
- ClinicalTrials.gov ID
- NCT07513337
- Acronym / sponsor ID
- IRB00034819
- Conditions
- Cannabis Use
- Keywords
- labeling and marketing, cannabis use, product perception
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,035 participants (actual)
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 15 Apr 2026 (actual)
- Primary completion
- 16 Jul 2026 (actual)
- Study completion
- 16 Jul 2026 (actual)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at how cannabis product label and marketing claims affect product perceptions, use expectancies, and use intentions among inexperienced and experienced cannabis users. Participants will answer online survey questions on their perceptions of a cannabis product advertisement.
Detailed description
This study aims to specify how product label and marketing claims affect product perceptions, use expectancies, and use intentions among cannabis users. A randomized 4 (Sativa, Indica, Hybrid, no strain label) x 3 (energizing, sedative, no claim) online experiment will be conducted with a sample of adults from states that have legalized adult cannabis recreational use. Our main research questions are: (1) Do label and marketing claim affect (a) harm perceptions, (b) subjective effects expectancies (e.g., arousal, sedation), (c) willingness to use, and (d) willingness to use during daily activities (e.g., driving)? and (2) Do label and marketing claim interact to affect product perceptions, use expectancies, and use intentions?
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 12
| Arm | Type | Receives |
|---|---|---|
| Indica/Energizing | Experimental | Other: Strain label, Other: ClaimAd features Indica label + energizing claim |
| Indica/Sedating | Experimental | Other: Strain label, Other: ClaimAd features Indica label + sedating claim |
| Indica/No claim | Experimental | Other: Strain labelAd features Indica label + no claim |
| Sativa/Energizing | Experimental | Other: Strain label, Other: ClaimAd features Sativa label + energizing claim |
| Sativa/Sedating | Experimental | Other: Strain label, Other: ClaimAd features Sativa label + sedating claim |
| Sativa/No claim | Experimental | Other: Strain labelAd features Sativa label + no claim |
| Hybrid/Energizing | Experimental | Other: Strain label, Other: ClaimAd features Hybrid label + energizing claim |
| Hybrid/Sedating | Experimental | Other: Strain label, Other: ClaimAd features Hybrid label + sedating claim |
| Hybrid/No claim | Experimental | Other: Strain labelAd features Hybrid label + no claim |
| No strain/Energizing | Experimental | Other: ClaimAd features no strain label + energizing claim |
| No strain/Sedating | Experimental | Other: ClaimAd features no strain label + sedating claim |
| No strain/No claim | No intervention | –Ad features no strain label + no claim |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age = 21+
- Live in in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
- For inexperienced users: lifetime cannabis use >1 \& <= 10
- For experienced users: lifetime cannabis use>10 \& <100, past month cannabis use>0
Key exclusion criteria (5 listed)
- Under age 21
- Does not live in a US state (or Washington D.C.) in which recreational cannabis sale is legal and implemented
- Lifetime cannabis use >=100 times
- Lifetime cannabis use <1 time
- Lifetime cannabis use>10 \& <100 AND past month cannabis use=0
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Strain labelPresentation of strain label on cannabis advertising material | Other | Hybrid/Energizing, Hybrid/No claim, Hybrid/Sedating, Indica/Energizing, Indica/No claim, Indica/Sedating, Sativa/Energizing, Sativa/No claim, Sativa/Sedating |
| ClaimPresentation of claim on cannabis advertising material | Other | Hybrid/Energizing, Hybrid/Sedating, Indica/Energizing, Indica/Sedating, No strain/Energizing, No strain/Sedating, Sativa/Energizing, Sativa/Sedating |
Primary outcome
Harm perception - One time use
Time frame: Immediately after viewing ad
How harmful participant perceives the product to be after one time use. Participants will answer a survey item, In your opinion, what is the level of risk to one's health from using the product you just viewed one time?; with response options ranging from 0-Very low risk to 4-Very high risk.
Harm perception - Daily use
Time frame: Immediately after viewing ad
How harmful participant perceives the product to be with daily use. Participants will answer a survey item, In your opinion, what is the level of health risk from using the product you just viewed on a daily basis?; with response options ranging from 0-Very low risk to 4-Very high risk.
Expectancy effects
Time frame: Immediately after viewing ad
Effects participant expects to feel after using the product. Participants will answer a survey item, Please rate the extent to which you expect to feel each of the following effects [paranoid; panicked; fearful; anxious; suspicious; like my heart is racing; sluggish; drowsy; out of it; slow; lazy; excited; heightened senses; sociable; creative; wise; in tune with nature; focused; productive; sleepy; happy; euphoric; calm; relaxed; pain-free] after using the product you just viewed; with response options ranging from 0-not at all to 10-extremely.
Willingness to use
Time frame: Immediately after viewing ad
How willing participant is to use the product. Participants will answer a survey item, How willing would you be to use the product you just viewed?; with response options ranging from 0-Not at all willing to 4-Very willing.
Willingness to use during daily activities
Time frame: Immediately after viewing ad
How willing participant is to use the product during daily activities. Participants will answer a survey item, How willing would you be to use the product you just viewed if you [wanted to concentrate; wanted to relax; wanted to socialize; wanted to do a creative activity (e.g., art, music); wanted to feel happier; wanted to relieve medical symptoms/treat a medical condition/mental health condition; were going to drive a car in the next 30 minutes; were going to bed in the next 30 minutes; were planning to stay home for the next several hours; were going to work in the next 30 minutes; were at a party]?; with response options ranging from 0-Not at all willing to 4-Very willing.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Individual participant dataSharing planned: Yes. Deidentified participant responses will be shared as needed to comply with grant and publication policies.
Related trials for Cannabis Use
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Meghan Moran, PhD principal investigator
Johns Hopkins University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Strain label and Claim in people with Cannabis Use, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Harm perception - One time use (time frame: Immediately after viewing ad). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.